证券代码：002317 公告编号：2024-078 广东众生药业股份有限公司 临床前研究结果表明，昂拉地韦对多种甲型流感病毒的抑制能力显著优于神 经氨酸酶抑制剂奥司他韦以及核酸内切酶抑制剂玛巴洛沙韦，并且对于奥司他韦 耐药的病毒株、玛巴洛沙韦耐药的病毒株和高致病性禽流感病毒株均具有很强的 抑制作用。昂拉地韦片（商品名：安睿威®）的新药上市申请正在审评审批阶段， 按照 CDE 要求正常推进中。 为方便特殊人群，包括儿童患者以及吞咽困难患者的用药，众生睿创开发了 昂拉地韦颗粒。昂拉地韦颗粒治疗 2~17 岁单纯性甲型流感患者的Ⅱ期临床试验， 在全国 32 家临床研究中心已陆续启动。在组长单位首都医科大学附属北京儿童 医院 PI 的指导下，众生睿创于近日完成该研究首例参与者入组和给药。众生睿 创将继续按照相关要求高质量、加速度、科学规范地推进昂拉地韦颗粒的Ⅱ期临 床试验。 二、对公司的影响及风险提示 昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组，对公司短期的财务状况、 第 1 页 共 2 页 关于控股子公司一类创新药昂拉地韦颗粒 Ⅱ期临床试验完成首例参与者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确 ...

证券代码：002317 公告编号：2024-077 广东众生药业股份有限公司 剂型：口服溶液剂 注册分类：化学药品 规格：10ml∶0.2g；60ml∶1.2g 申请内容：申请增加规格；申请增加儿童专用规格 关于全资子公司获得羧甲司坦口服溶液 《药品补充申请批准通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）全资子公司广东华南药业 集团有限公司于近日收到国家药品监督管理局核准签发的羧甲司坦口服溶液《药 品补充申请批准通知书》。现将相关情况公告如下： 一、药品补充申请批准通知书主要信息 药品名称：羧甲司坦口服溶液 根据米内网数据库显示，羧甲司坦口服溶液 2021 至 2023 年在中国城市公立 医院及中国城市实体药店的销售总额合计为人民币 53,715 万元，56,544 万元， 81,882 万元。 药品批准文号：国药准字 H20247266；国药准字 H20247267 上市许可持有人：名称：广东华南药业集团有限公司，地址：东莞市石龙镇 西湖工业区信息产业园 生产企业：名称：广东众生药业股份有限公司 ...

Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Views - The company's Q3 2024 performance shows short-term pressure, with revenue of 1.908 billion yuan, down 7.9% year-on-year, and a net profit of 150 million yuan, down 46.8% year-on-year. The third quarter revenue was 544 million yuan, down 7.7% year-on-year, with a net profit of 61 million yuan, down 13.5% year-on-year [1]. - The impact of traditional Chinese medicine procurement is gradually clearing, allowing the company to adopt targeted marketing strategies to maintain its competitive advantage in core products. The report anticipates a recovery in product usage and a potential increase in volume despite price reductions [1]. - The company has made progress in innovation, with one innovative drug approved for market and several others in clinical trials. The establishment of a multi-modal research and development ecosystem is expected to drive long-term performance [1]. Financial Summary - For 2024-2026, the company is projected to achieve net profits of 251 million yuan, 363 million yuan, and 425 million yuan, with corresponding growth rates of -4.8%, 44.6%, and 17.1% respectively. The price-to-earnings ratios are estimated at 45X, 31X, and 26X [1][2]. - The company's revenue for 2024 is expected to be 2.69 billion yuan, with a growth rate of 3.0%. The net profit for 2024 is projected at 251 million yuan, reflecting a decline of 4.8% year-on-year [2][9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [11]. Core Views - The company is experiencing short-term pressure on performance, with a reported revenue of 1.91 billion yuan for the first three quarters of 2024, a year-on-year decline of 7.9%, and a net profit attributable to shareholders of 150 million yuan, down 46.8% year-on-year [1][3]. - The company is focusing on innovation in drug development, with significant progress in its pipeline, including the launch of a new drug for COVID-19 and another drug for influenza currently under review [2][3]. Financial Performance Summary - For the first three quarters of 2024, the gross margin was 56.1%, a decrease of 4.3 percentage points year-on-year, while the sales expense ratio increased to 33.9% [2]. - The company’s net profit forecast for 2024-2026 has been revised downwards, with expected net profits of 220 million, 350 million, and 410 million yuan respectively, corresponding to P/E ratios of 50, 32, and 27 [3][6]. - The company reported a gross margin of 54% in Q3 2024, down 3.1 percentage points year-on-year, with an increase in the sales expense ratio to 37.4% [2]. Innovation Pipeline - The company has a robust innovation pipeline, with key products such as RAY1225, a dual-target innovative drug for diabetes and weight loss currently in Phase II clinical trials, and ZSP1601, an innovative drug for non-alcoholic fatty liver disease, also in Phase IIb trials [2].

证券代码：002317 公告编号：2024-076 广东众生药业股份有限公司 关于使用部分闲置自有资金进行委托理财及 募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 了第八届董事会第十五次会议及第八届监事会第十五次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资计划正常进行的情况下，使用不超过人民币 28,000.00 万元的闲置募集资金 进行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。现金 管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限内资金可 滚动使用，但在任一时点的实际投资金额不超过人民币 28,000.00 万元，本次使 用部分闲置募集资金进行现金管理事项将在上述额度内，授权董事长具体实施相 关事宜。 公司于 2024 年 10 月 26 日召开了第八届董事会第十六次会议和第八届监事 会第十六次会议，审议通过了《关于使用闲置自有资金进行委托理财 ...

证券代码：002317 公告编号：2024-075 广东众生药业股份有限公司 关于控股子公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司董事会 二〇二四年十月二十九日 第 1 页 共 1 页 具体变更情况如下： | 变更项目 | 变更前 | 变更后 | | --- | --- | --- | | 法定代表人 | 龙超峰 | 陈小新 | 特此公告。 近日，广东众生药业股份有限公司收到控股子公司广东众生睿创生物科技有 限公司（以下简称"众生睿创"）完成工商变更登记的通知。经广州市黄埔区市 场监督管理局核准，众生睿创已办理完成工商变更登记手续，并取得新的《营业 执照》。 ...

证券代码：002317 公告编号：2024-072 广东众生药业股份有限公司 证券代码：002317 公告编号：2024-072 经审核，监事会认为董事会编制和审核《公司 2024 年第三季度报告》的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 二、审议通过了《关于使用闲置自有资金进行委托理财的议案》。 经审核，监事会认为公司及子公司（公司合并报表范围内的子公司）本次使 用闲置自有资金进行委托理财事项是在不影响正常生产经营以及项目建设的前 提下进行，并履行了必要的审批程序，投资决策程序符合相关法律法规的要求， 不会对公司的经营活动造成不利影响，同时有利于提高公司资金的使用效率，不 存在损害公司及中小股东利益的情形。同意公司及子公司使用不超过人民币 70,000.00 万元的闲置自有资金进行委托理财。 表决结果：3 票同意，0 票反对，0 票弃权。 第 1 页 共 2 页 第八届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 ...

证券代码：002317 公告编号：2024-071 广东众生药业股份有限公司 第八届董事会第十六次会议决议公告 同意公司及子公司（公司合并报表范围内的子公司）在保障日常生产经营以 及项目建设资金需求，有效控制风险的前提下，使用不超过人民币 70,000.00 万 元的闲置自有资金进行委托理财，期限为本次董事会审议通过之日起十二个月内， 期限内任一时点的交易金额不超过人民币 70,000.00 万元。在上述期限及额度内， 资金可滚动使用。本投资事项将在上述额度内，授权董事长具体实施相关事宜。 表决结果：9 票同意，0 票反对，0 票弃权。 备注：《关于使用闲置自有资金进行委托理财的公告》详见信息披露媒体： 《证券时报》和巨潮资讯网（www.cninfo.com.cn）。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第十六次会 议的会议通知于 2024 年 10 月 16 日以专人和电子邮件形式送达全体董事，会议 于 2024 年 10 月 26 日在公司会议室以现场和通讯表决方式召开。本次会议应出 席董 ...

证券代码：002317 公告编号：2024-074 广东众生药业股份有限公司 关于使用闲置自有资金进行委托理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、委托理财种类：安全性高、流动性好具有合法经营资格的金融机构销售 的理财类产品或存款类产品。 2、委托理财金额：额度为期限内任一时点的委托理财交易金额不超过人民 币 70,000.00 万元，在上述额度内，资金可以滚动使用。 3、特别风险提示：广东众生药业股份有限公司（以下简称"公司"）使用 闲置资金购买理财产品是公司在风险可控的前提下提高闲置资金使用效率的理 财方式，风险较低。但受宏观经济形势变化或市场波动等影响，委托理财的实际 收益存在不确定性，敬请广大投资者注意投资风险。 为提高资产使用效率和现金资产的收益，公司于 2024 年 10 月 26 日召开第 八届董事会第十六次会议和第八届监事会第十六次会议，审议通过《关于使用闲 置自有资金进行委托理财的议案》，同意公司及子公司（公司合并报表范围内的 子公司）在保障日常生产经营以及项目建设资金需求，有效控制风险的前提下， 使用不 ...

Financial Performance - Revenue for Q3 2024 was CNY 543,655,317.04, a decrease of 7.70% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 61,392,645.92, down 13.46% year-on-year[3] - Net profit excluding non-recurring gains and losses was CNY 14,719,589.15, a significant decline of 79.17% compared to the previous year[3] - Total operating revenue for the third quarter of 2024 was CNY 1,908,022,039.84, a decrease of 7.87% from CNY 2,071,278,555.78 in the same period last year[20] - Operating profit decreased to CNY 236,330,273.87, down 25.14% from CNY 315,884,900.52 year-over-year[21] - Net profit for the third quarter was CNY 135,910,863.59, a decline of 51.24% compared to CNY 279,214,968.42 in the previous year[21] - The net profit attributable to the parent company for Q3 2024 is ¥148,802,427.39, a decrease of 46.7% compared to ¥279,495,705.55 in the same period last year[22] - The total comprehensive income for Q3 2024 is ¥135,462,397.95, down from ¥282,956,241.04 in Q3 2023, reflecting a decline of 52.2%[22] - The basic earnings per share for Q3 2024 is ¥0.18, compared to ¥0.34 in Q3 2023, indicating a decrease of 47.1%[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,820,046,447.21, reflecting a decrease of 9.89% from the end of the previous year[3] - The company’s total liabilities decreased significantly, with short-term borrowings down 100% to CNY 0 as a result of repayment[7] - Total liabilities decreased to CNY 1,276,882,550.22 from CNY 1,932,845,785.58, reflecting a reduction of 33.93%[19] - The company's total equity increased slightly to CNY 4,543,163,896.99 from CNY 4,525,676,613.51, representing a growth of 0.39%[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 300,460,401.93, an increase of 439.98%[3] - Net cash flow from operating activities increased by 439.98% to 300,460,401.93, attributed to cost reductions in response to centralized procurement and last year's early raw material purchases[8] - The net cash flow from operating activities for Q3 2024 is ¥300,460,401.93, significantly up from ¥55,643,062.22 in the same period last year, representing an increase of 438.5%[23] - The net cash flow from investment activities for Q3 2024 is ¥120,624,174.08, a turnaround from a negative cash flow of ¥189,399,577.93 in the same period last year[23] - The net cash flow from financing activities for Q3 2024 is -¥862,477,661.14, compared to a positive cash flow of ¥818,959,164.52 in Q3 2023, indicating a significant decline[24] - The cash and cash equivalents at the end of Q3 2024 amount to ¥760,317,475.01, down from ¥1,597,855,253.30 at the end of Q3 2023, a decrease of 52.5%[24] Investments and Subsidiaries - The company reported a significant increase in long-term equity investments by 101.24% to CNY 3,653,444.06 due to increased equity method investment income[7] - The company’s long-term equity investments increased from CNY 1,815,466.82 to CNY 3,653,444.06, reflecting a growth of approximately 101.1%[18] - The company’s subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., received approval for a Phase II clinical trial of the innovative drug ZSP1273 for treating influenza in patients aged 2 to 17[14] - The company obtained a drug registration certificate for the innovative drug Lurivite (brand name: Le Ruixing®) in Macau, enabling sales in the region[15] - The company has completed the deregistration of its subsidiary Guangdong Zhonglong Chuangcheng Biotechnology Co., Ltd., aligning with its strategic focus on core business operations[15] - The innovative polypeptide drug RAY1225 injection has received acceptance for a clinical trial application for the treatment of Metabolic Associated Steatotic Liver Disease (MASH)[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 88,576[10] - Major shareholders Zhang Yuchong and Zhang Yuli each hold 10.88% of shares, totaling 92,640,500 shares[10] - The company transferred 5,551,000 shares to the 2024 employee stock ownership plan, representing 0.65% of the total share capital, at a price of 6.68 per share[13] Expenses - Research and development expenses increased to CNY 86,091,412.48, up 6.06% from CNY 81,119,346.81 year-over-year[21] - The company reported a decrease in sales expenses to CNY 645,880,775.21, down 7.33% from CNY 696,811,016.60[21] - The company reported a 3,220.61% increase in non-operating expenses to 58,696,945.18, primarily due to increased provisions for pending litigation and inventory write-offs[8] - Financial expenses decreased by 64.92% to 6,188,357.25 due to reduced interest expenses from decreased bank loans[8] Other Financial Metrics - The company recorded a credit impairment loss of -6,935,540.55, a 79.20% increase due to increased provisions for bad debts[8] - The company reported a decrease in cash and cash equivalents from CNY 1,252,043,320.29 at the beginning of the period to CNY 766,131,361.53 at the end of the period, representing a decline of approximately 38.7%[17] - The total current assets decreased from CNY 3,960,606,763.22 to CNY 3,260,603,051.47, a reduction of about 17.7%[18] - The company received government subsidies amounting to CNY 1,282,860.20 during the reporting period[4] - The deferred income tax liabilities decreased to CNY 38,173,024.39 from CNY 48,950,943.30, a reduction of 22.01%[19] - The cash inflow from investment activities for Q3 2024 is ¥1,116,898,539.09, compared to ¥412,901,267.65 in Q3 2023, marking an increase of 170.6%[23] - The company received cash from operating activities totaling ¥1,912,197,257.31 in Q3 2024, slightly down from ¥1,943,273,734.78 in Q3 2023, reflecting a decrease of 1.6%[23] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -¥448,465.64 in Q3 2024 compared to ¥3,741,272.62 in Q3 2023[22]